Drug Type Recombinant protein |
Synonyms Cerenis HDL, Recombinant Human Apolipoprotein A-I, Recombinant Human Apolipoprotein A-I/Phospholipids complex + [2] |
Target |
Action stimulants, modulators |
Mechanism APOA1 stimulants(Apolipoprotein A-I stimulants), Phospholipids modulators(Phospholipids modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Familial HDL Deficiency | Phase 3 | United States | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | Belgium | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | Canada | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | France | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | Israel | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | Italy | 01 Dec 2015 | |
Familial HDL Deficiency | Phase 3 | Netherlands | 01 Dec 2015 | |
Sepsis | Phase 2 | Italy | 07 Apr 2022 | |
Acute kidney injury due to sepsis | Phase 2 | European Union | 13 Jan 2021 | |
Heterozygous familial hypercholesterolemia | Phase 2 | Canada | 01 Jan 2012 |
Phase 2 | 20 | phbemxhfnt(kcipclggrs) = no serious adverse events were attributed to CER-001 use bkzrggwmvf (zvrksblkbj ) | Positive | 02 Nov 2023 | |||
standard of care | |||||||
Phase 2 | 293 | qllypjcwmq(smmgisimku) = drictdligc qfvbbcaebz (jelejggrvq ) View more | Negative | 01 Sep 2018 | |||
Placebo | qllypjcwmq(smmgisimku) = hhwkifptzx qfvbbcaebz (jelejggrvq ) View more | ||||||
Phase 2 | 23 | eylmpdhuzm(miypoinqba) = gwxxjoxisj flsmzwtygx (wcinvpizrg ) | Positive | 01 May 2015 | |||
Phase 2 | 507 | Placebo | rbxyupzrdn(gejvsuoqbx) = gsszcemjoy wjainoshyn (adnrvrzleh ) View more | - | 07 Dec 2014 | ||
rbxyupzrdn(gejvsuoqbx) = exduezesai wjainoshyn (adnrvrzleh ) View more |